Nava Therapeutics debuts with $89M seed to steer lipid nanoparticles

What's the deal? Nava Therapeutics, a secretive startup, has emerged with an $89 million seed round, the company announced in July 2026. It is developing a new generation of lipid nanoparticles designed to target the bone marrow, immune cells, and the kidney.

What's the endgame? Lipid nanoparticles are the delivery vehicles that carry genetic payloads into cells. Nava is aiming its versions at T cells and the kidney, expanding where these particles can reach beyond the liver, which most current systems favour.

Why now? The company had operated quietly before this reveal. The seed round gives it capital to advance work that could open new therapeutic targets in cell and gene medicine.

The signal: An $89 million seed is unusually large. Among all US health seed rounds tracked, it sits in the 99th percentile — a sign of investor appetite for delivery technology that can widen the reach of genetic medicines.

Read more: Endpoints News

Image credit: National Institutes of Health (NIH)